| Bioactivity | GSK-3β inhibitor 22 (compound 20o) is a GSK-3β inhibitor with an IC50 of 3.1 nM. GSK-3β inhibitor 22 has the potential of the study of Alzheimer's disease[1]. | |||||||||
| CAS | 1005199-84-7 | |||||||||
| Formula | C18H12F3N3O2S2 | |||||||||
| Molar Mass | 423.43 | |||||||||
| Appearance | 固体 | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Morihisa Saitoh, et al. Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta. Bioorg Med Chem. 2009 Mar 1;17(5):2017-29. |
GSK-3β inhibitor 22
CAS: 1005199-84-7 F: C18H12F3N3O2S2 W: 423.43
GSK-3β inhibitor 22 (compound 20o) is a GSK-3β inhibitor with an IC50 of 3.1 nM. GSK-3β inhibitor 22 has the potentia
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.